Functional variant of IL33 is associated with survival of osteosarcoma patients
Conclusions: Variant rs55933544 was associated with the survival time of OS patients. IL33 may contribute to a poor prognosis of OS. Further investigation into the biological mechanisms by which IL33 influences the overall survival can shed light on the improvement of clinical outcome for OS patients. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 3, 2019 Category: Cancer & Oncology Source Type: research
The immune landscape of chondrosarcoma reveals an immunosuppressive environment and exposes macrophages as a promising therapeutic target
Publication date: Available online 26 November 2019Source: Journal of Bone OncologyAuthor(s): Richert Iseulys, Gomez-Brouchet Anne, Bouvier Corinne, Du Bouexic De Pinieux Gonzague, Karanian Marie, Blay Jean-Yves, Dutour AurélieAbstractSurvival rate for Chondrosarcoma (CHS) is at a standstill, more effective treatments are urgently needed. Consequently, a better understanding of CHS biology and its immune environment is crucial to identify new prognostic factors and therapeutic targets.Here, we exhaustively describe the immune landscape of conventional and dedifferentiated CHS. Using IHC and molecular analyses (RT-qPCR), w...
Source: Journal of Bone Oncology - November 27, 2019 Category: Cancer & Oncology Source Type: research
Evaluating the Scope of Intramedullary invasion of Malignant Bone Tumor by DCE-MRI Quantitative Parameters in Animal study
ConclusionQuantitative parameters Ktrans, Kep and ve can assess the extent of intramedullary invasion of malignant bone tumors. Ktrans have highest accuracy in differentiating different regions. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 20, 2019 Category: Cancer & Oncology Source Type: research
A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival
In this study we aimed at identifying kinase inhibitors that inhibit the survival of chondrosarcoma cells and thereby serve as new potential therapeutic strategies to treat chondrosarcoma patients.An siRNA screen targeting 779 different kinases was conducted in JJ012 chondrosarcoma cells in parallel with a compound screen consisting of 273 kinase inhibitors in JJ012, SW1353 and CH2879 chondrosarcoma cell lines. AURKA, CHK1 and PLK1 were identified as most promising targets and validated further in a more comprehensive panel of chondrosarcoma cell lines. Dose response curves were performed using tyrosine kinase inhibitors: ...
Source: Journal of Bone Oncology - November 18, 2019 Category: Cancer & Oncology Source Type: research
Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis
ConclusionThis study includes preliminary clinical data of SCLC patients with bone metastases at the time of diagnosis, and more studies are needed. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research
Analgesia of Percutaneous Thermal Ablation Plus Cementoplasty for Cancer Bone Metastases
Conclusions: Our systematic review suggested that thermal ablation combined with cementoplasty could be a safe and effective intervention for the management of bone metastases-induced pain. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 5, 2019 Category: Cancer & Oncology Source Type: research
Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis: a simple scoring system predicting survival
ConclusionThis study demonstrates preliminary clinical data of SCLC with bone metastases at the time of diagnosis, and more studies are needed. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 3, 2019 Category: Cancer & Oncology Source Type: research
Clear cell chondrosarcoma is an underestimated tumor: Report of 7 cases and meta-analysis of the literature
Conclusions: A wide resection is the advocated treatment option. Long term follow-up for at least 10 years is necessary in order to not overlook late LR or MD. This work demonstrates for the first time the apparent aggressiveness of the CCC. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - November 1, 2019 Category: Cancer & Oncology Source Type: research
Use of endoprostheses for proximal femur metastases results in a rapid rehabilitation and low risk of implant failure. A prospective population-based study
ConclusionsEndoprosthesis for treatment of MBDf results in low implant failure. Patients are satisfied with the functional outcome. QoL is restored six-weeks after surgery. Authors advocate for caution using internal fixation for MBDf due to findings of possible early postoperative revision risk. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 22, 2019 Category: Cancer & Oncology Source Type: research
Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma
ConclusionThis study shows that the radiomics signature extracted from pre-treatment DWI-MRI improve prediction of OS over clinical features alone. Combination of the radiomics signature and the traditional clinical risk factors performed better for individualized OS estimation in patients with osteosarcoma, which might enable a step forward precise medicine. This method may help better select patients most likely to benefit from intensified multimodality diagnosis and therapies. Future studies will focus on multi-center validation of an optimized model. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - October 5, 2019 Category: Cancer & Oncology Source Type: research
Diagnostic accuracy of functional imaging modalities for chondrosarcoma: A systematic review and meta-analysis
ConclusionsLow-grade chondrosarcomas continue to pose a diagnostic dilemma. FDG-PET demonstrated superior diagnostic accuracy compared to Tc-99m MDP, Thallium-201 and Tc-99m DMSA (V). Characteristic uptake patterns of Thallium-201 and Tc-99m DMSA (V) may provide additional metabolic information to guide the diagnosis in this challenging group of tumours. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - September 26, 2019 Category: Cancer & Oncology Source Type: research
An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
Publication date: Available online 18 September 2019Source: Journal of Bone OncologyAuthor(s): Sarah Danson, Matthew R Mulvey, Lesley Turner, Janet Horsman, K Jane Escott, Robert E Coleman, Sam H Ahmedzai, Michael I Bennett, David AndrewAbstractPain is a major symptom of bone metastases from advanced cancer and represents a clinical challenge to treat effectively. Basic neurobiology in preclinical animal models implicates enhanced sensory processing in the central nervous system, acting through N-methyl-D-aspartate (NMDA) glutamate receptors, as an important mechanism underpinning persistent pain. The non-receptor tyrosine...
Source: Journal of Bone Oncology - September 18, 2019 Category: Cancer & Oncology Source Type: research
The bone metastasis niche in breast cancer: potential overlap with the haematopoietic stem cell niche in vivo
Conclusion: Our data provide evidence that homing of breast cancer cells is independent of their ER status and that the breast cancer bone metastasis niche is located within the trabecular region of bone, an area rich in osteoblasts and microvessels. The increased number of breast cancer cells homing to bone after mobilisation of HSCs suggests that the HSC and the bone metastasis niche overlap. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - September 13, 2019 Category: Cancer & Oncology Source Type: research
Survival and prognosis in malignant giant cell tumor of bone: a population-based analysis from 1984 to 2013
ConclusionThis study provides a population-based assessment of the largest number of patients with MGCTB. We found that older age, larger tumor size, regional or distant metastasis, and lack of radiotherapy was associated with poor OS. Surgical methods were not significantly associated with OS. Furthermore, we built a high-quality nomogram to predict 1-, 3-, and 5-year OS for patients with MGCTB. These findings may assist in the clinical diagnosis and treatment of MGCTB. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - September 11, 2019 Category: Cancer & Oncology Source Type: research
Atypical femoral fractures from bisphosphonate in cancer patients – Review
Publication date: Available online 22 August 2019Source: Journal of Bone OncologyAuthor(s): Matthew Lockwood, Rajesh Banderudrappagari, Larry J. Suva, Issam MakhoulAbstractBisphosphonates are commonly used in patients with metastatic bone disease to prevent skeletal related events. Atypical femur fracture is a known complication of long-term bisphosphonate use but the incidence in cancer patients and pathogenesis are not well known. Several mechanisms of pathogenesis have been proposed including altered angiogenesis, altered bone mechanical properties, micro damage and bone remodeling suppression. Atypical femur fractures ...
Source: Journal of Bone Oncology - August 24, 2019 Category: Cancer & Oncology Source Type: research
